Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

AbbVie and Shire in Talks Over $53 Billion Merger

14/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzmvmjyvntm3l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0


The Irish drug maker Shire said on Monday that its board was prepared to recommend an improved takeover bid received over the weekend from AbbVie, pending further discussions, paving the way for a merger.

In its latest bid, AbbVie, based in Chicago, has offered to pay cash and stock equal to about 53.20 pounds a share for Shire. That is the equivalent of roughly £31 billion, or about $53 billion.

AbbVie, the maker of the arthritis drug Humira, had previously offered to pay about $51 billion for Shire, which makes Vyvanse and Adderall XR, treatments for attention deficit hyperactivity disorder.

The deal, if completed, would allow AbbVie to reincorporate in Britain and save millions of dollars in taxes in a process known as an inversion. Shire has its headquarters in Ireland and is listed in London.

“The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders subject to satisfactory resolution of the other terms of the offer,” Shire said in a statement on Monday. “The board is in detailed discussions with AbbVie in relation to these terms.”

The health care sector has been one of the most active for deals this year, with an estimated $328.8 billion announced through July 10 – a 207 percent increase from the period a year earlier, according to Thomson Reuters.

Pharmaceutical companies in particular have been eager to take advantage of inversions, in which they reincorporate outside the United States to lower their corporate taxes and free up money that has been trapped overseas.

This article has been extracted from http://dealbook.nytimes.com, please click on this link to read the article in full http://dealbook.nytimes.com/2014/07/14/shire-and-abbvie-in-talks-over-53-billion-pharmaceutical-merger/?_php=true&_type=blogs&_r=0

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdevmjavmtavntyvmtkvnzgzl0nsts5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Salesforce moves into Seattle with new engine...

2017-01-20 10:00:00 +0000

Salesforce, a world leader in customer relationship management (CRM) solutions, has revealed that it is to open an innovation and engineering hub in Seattle. In order to increase the firm’s presence in the city, Salesforce Co-Founder Parker Harris said that the office located in Bellevue’s Nine Two Nine Office Tower will focus on its artificial intelligence (AI) initiatives. One reason for the move is so that the firm can access a new pool of talent. Ta...

W1siziisijiwmtcvmdevmtgvmdkvmtqvmzmvmzk5l0vsuc5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Sage bolsters X3 business ERP solution

2017-01-18 09:00:00 +0000

Sage, one of the global leaders in enterprise resource planning (ERP) solutions, has revealed that it has signed up a trio of new clients to its X3 business solution. With the Salesforce.com partner wanting to be able to show its ability to host larger clients, the firm revealed that BrightBridge, Atlas Cloud and CLOUT are all now utilising the new and emerging X3 ERP platform. Sage Vice President of UK Enterprise David Watts talked about the latest agr...